Writing Plain Language Summaries in Accordance with the new EU Guidelines

Carmen E. Aldinger, PhD, MPH
Program Manager
Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard
The opinions contained herein are those of the authors and are not intended to represent the position of Brigham and Women's Hospital or Harvard University.

The MRCT Center is supported by voluntary contributions from foundations, corporations, international organizations, academic institutions and government entities (see www.MRCTCenter.org) and well as by grants.

We are committed to autonomy in our research and to transparency in our relationships. The MRCT Center—and its directors—retain responsibility and final control of the content of any products, results and deliverables.
Engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.
Objectives of today’s presentation

- Review the new EU guideline’s recommendations for summarizing clinical trial results for laypeople
- Learn how to return results consistent with the EU guidelines, utilizing the MRCT Center Toolkit and Guidance Document
- Apply health literacy, numeracy and readability standards to plain language summaries
- Weigh the benefits of planning for plain language summaries in the early stages and throughout the clinical trial
Rationale for returning plain language summaries to participants
A Word on Terminology

• In the U.S., change in progress from “lay summaries” to “plain language summaries” (PLS)

• We use the term “plain language:”
  – Feedback from patient groups indicated a more positive reaction to this term as compared to “lay” summary

• EU Guideline refers to “Summaries of Clinical Trial Results for Laypersons”

Sponsor of a clinical trial must submit “a summary of the results of the clinical trial together with a summary that is understandable to a layperson, and the clinical study report, where applicable, within the defined timelines.”

**Article 37:** Irrespective of the outcome of a clinical trial, within one year from the end of a clinical trial in all Member States concerned, the sponsor shall submit to the EU database a summary of the results of the clinical trial.

EU requires posting laypersons summary to EU Portal beginning in Oct 2018
EU Guidelines on Summaries of Clinical Trial Results to Laypersons

- Has been approved by ad-hoc committee in January 2017
- Has not been publicly released
## Patient/Participant Perspective in the U.S.

<table>
<thead>
<tr>
<th>Patients / Study Volunteers</th>
<th>Research Professionals</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 90% want to know the results of their clinical trial&lt;sup&gt;1&lt;/sup&gt;</td>
<td>• 98% of study staff would like to provide results to their volunteers&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>• 91% never hear back from study staff or sponsor&lt;sup&gt;2&lt;/sup&gt;</td>
<td>• 95% of research ethics board chairs strongly support (Canadian survey)&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>• If not informed, 68% would not participate in future trials&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

Recent small studies with participants and patients of comprehensive and integrative medicine from New England confirmed: 89—90 % want researchers to share results, 16—37 % received their results

---

Multi-Regional Clinical Trials Center Response
The MRCT Center Tools

- **Return of Aggregate Results Guidance Document**
  (Version 3.0, March 2017)

- **Return of Aggregate Results Toolkit**
  (Version 3.0, March 2017)

- **Return of Aggregate Results to Participants Principles**
  (Version 1.0, December 2016)
• **Version 3.0 released in March 2017**

  Major changes:
  • Changed terminology to Plain Language Summaries (PLS)
  • Changed headings for PLS to correspond with EU Guidelines
  • Revised Basic Principles

  Content:
  • Overview, including role of IRB/REC
  • Organizational process and logistics
  • Content of plain language summaries
  • Special considerations
  • Appendices, including Health Literacy and Numeracy

  Link:
Return of Aggregate Results Principles

- Released in December 2016

Content
- 8 Principles that summarize the foundation of returning aggregate results to participants

Principles for returning aggregate results

1. Participants or their designees should be the recipients of research results summaries.

2. Returning results to trial participants respects their volunteerism and their partnership in research; we recommend, therefore, that sponsors offer to provide results to study participants for *all* clinical studies.

3. Sponsors should prepare and disseminate research results summaries in a manner that is fair, balanced, factual and non-promotional.

4. Research results summaries should be written clearly and concisely, employing a patient-centric approach and incorporating principles of health literacy, cultural literacy and numeracy.
5. When offered, participants should be able to choose whether or not to receive research results summaries.

6. Considerations pertaining to the return of aggregate research results to trial participants should be integrated into the clinical trial and proactively planned.

7. Clinical research sites should support and participate in the dissemination of research summaries to all study participants who wish to receive results.

8. Return of aggregate results should be planned and executed in compliance with institutional policies and local, regional, and national laws and regulations.
Return of Aggregate Results Toolkit

• **Version 3.0 released in March 2017**
  
  Major changes:
  
  • Revised Template for Communication of Study Results to correspond with headings of EU Guidance
  
  Content:
  
  • Template for communication of study results
  • Checklist for plain language summaries reviewers
  • Endpoint table with sample language
  • Neutral language guidance
  • Ethics committee checklist for aggregate plain language summaries
  • Examples from external sources
  
  Link:
  
1. Study name
2. Who sponsored this study?
3. General information about the clinical trial
4. What patients/people were included in this study?
5. Which medicines [or vaccines] were studied?
6. What were the side effects?
7. What were the overall results of the study?
8. How has this study helped patients and researchers?
9. Are there plans for future studies?
10. Where can I find more information about this study?
Essential Elements of Plain Language Summaries

1. Study name
   - Plain, simple language
   - Full title is required by U.K. guidelines
   - Summary includes only results from one single study

2. Who sponsored this study?
   - List all sponsors
   - Contact information

3. General information about the clinical trial
   - Start and stop dates
   - Countries
   - Why the study was important
4. What patients/people were included in this study?
   – Number enrolled, age and gender
   – Description of specific population and how chosen
   – Results apply only to this population

5. What medicines [or vaccines] were studied?
   – Simple explanation of study arms, consider graphic
   – Clarify that this is only one study in drug development process

6. What were the side effects?
   – Common and serious medical issues
7. What were the overall results of the study?
   – Take-home message (like abstract to a paper)
   – Results per study arm
   – Neutral (non-promotional), simple language

8. How has this study helped patients and researchers?
   – Research helps future patients
   – Results applicable to the specific population studied
   – Limitations of the study

9. Are there plans for further studies?
   – Information about related trials, ongoing or planned
10. Where can I find more information about this study?
   – Official number and title
   – Links to related (non-promotional/generic) websites

• Don’t forget:
  – Thank you
  – Date
• A Pilot Study on a Mind-Body Intervention for Irritable Bowel Syndrome and Inflammatory Bowel Disease
Health Literacy Principles: Overview

- Plain language – check reading scores
- Use active voice and short sentences
- Formatting to aid comprehension:
  - Presentation of the “big picture” before the details
  - Headlines to organize information
  - Descriptive headers and subheadings
  - Limited use of tables and charts
  - Adequate “white space”
  - Minimum of 12-point font
  - Sufficient contrast between font and background color
  - Avoidance of text in ALL CAPS
- For more information: Appendices 3 and 4 of Guidance Document
Researchers were looking for a better way to treat knee pain in people with osteoarthritis. Osteoarthritis is a degenerative disease that involves the degradation of articular joints and subchondral bone, as a result of mechanical stress on the area.

In plain language:

- Osteoarthritis refers to a progressive joint disease or “wear and tear.” This is the most common illness of the joints. It occurs when the cartilage or cushion between joints breaks down. This leads to stiffness, swelling and pain.

- Scores:
  - Flesch Reading Ease: 72.5 (recommended between 60 and 70, the higher the score, the easier to understand)
  - Flesch-Kincaid Grade Level: 5.5 (recommended 6-8; the lower the easier to understand)

From: Strategies to Enhance Numeracy Skills

• Marry words and numbers to provide a complete understanding
• Do the math
• Be consistent
• Present only the most necessary information, but enough to be fully understood
• Be visual – use images and shapes to reflect the meaning of the numbers
• Be aware of how you present or describe a risk
• Check in early and often

(Accessed: June 16, 2017)
Planning for plain language summaries throughout the clinical trial process

• Before the study starts
  – Update organizational policies, processes, procedures
  – Establish level / timing / delivery method of PLS
  – Budget for PLS
  – Develop and incorporate PLS into study documents (e.g., informed consent, communication and publication plan)
  – Build staff capacity
• Protocol development
  – Anticipate that participants will be given an opportunity to receive study results

• Informed consent development
  – Include a general statement that explains the intent to provide PLS
  – Example: “In the future, you can decide whether or not you wish to receive the general results of the study. You do not need to decide now about this.”

• Resource planning
  – Discuss and agree upon resources for PLS execution
• During study conduct
  – Discuss Informed Consent with participant: process and anticipated timing of PLS
  – Prepare for participant end-of-study visit: written summary, including opt-in or opt-out for receiving aggregate results; if opted-in, how to access PLS when available
  – Stay connected with participant; e.g., thank you letter after ICF is signed, letter of appreciation after last visit, annual holiday card, periodic letters explaining stage of the study
Planning for plain language summaries throughout the clinical trial process (cont.)

- After study ends or all data for primary endpoint concluded
  - Develop PLS according to template
  - Have PLS reviewed by clinical trial team and medical communications group, and, optimally, internal and/or external reviewers with varied backgrounds
  - Identify study participants who agreed to receive PLS and notify them
New Resources

• Trial Scope
  – Searchable Portal for trial results summaries (search by keyword, condition, location, first or last visit date)
  – https://www.trialsummaries.com/Home/LandingPage

• Health Literacy Media
  – Write, edit, review and design health materials in plain language
  – Conduct national and international initiatives that apply health literacy best practices, etc.
  – http://www.healthliteracy.media/
Create plain language summaries (PLS) according to template with new headings

Integrate plans for PLS before the study begins, throughout the study, and after study ends

Apply health literacy and numeracy principles

Utilize available resources
Outlook

- Return of results to participants may become the expectation and practice in clinical research.

- Funding and resources for return of results and training for writing summary results should be provided as an anticipated component of human subjects research.

- Logistics, content, processes, standard methodologies and approaches must be delineated for populations inside and outside of US, UK and EU.
Next Steps for the MRCT Center Efforts

• Recommendations Document and Toolkit for Return of Individual Results
• Results from small studies on return of results in integrative medicine, using PLS template
• E-Learning course for return of aggregate results
• Updates for Return of Aggregate Results Recommendations Document and Toolkit, as needed
Carmen E. Aldinger, PhD, MPH
Program Manager

caldinger@bwh.harvard.edu | http://MRCTcenter.org/

Go to “Resources” – “Return of Aggregate Results”